View All
May 04, 2020

Qrumpharma Works To Tackle Covid-19

During these uncertain times as we collectively face the challenges of the Coronavirus pandemic, we at Qrumpharma (Doylestown) continue our efforts to alleviate lung disease by using our experience in these areas:

Fighting lung diseases including the novel Coronavirus by working to develop an inhaled form of Clofazimine. While this drug is intended to treat Tuberculosis and a related pathogen called Nontuberculous mycobacteria (NTM) we have recently found that it may be useful in the treatment of SARS-Cov2 Coronavirus. We are currently conducting animal studies of this potential treatment through government and private funding.

We are also involved with another inhaled medication approach to treat Covid-19 and have made our knowledge of that treatment available to a partner company in Europe.

Simultaneously, we continue our progress towards new therapies for Tuberculosis and NTM which remain killers of people and cause severe damage to the lungs of those effected.

We are also working with our wonderful colleagues at the Pennsylvania Biotech Center (including Dr. Block, Dr. Kassa, Dr. Bick, and Dr. Capocasale) to bring increased an number of validated tests for SARS-Cov2 Coronavirus to our county, state and region. We know that testing is a solution to protecting people and opening our society and economy.

In our leisure time our principal, and your neighbor, Dr. Thomas Hofmann enjoys spending time on his Bianchi road bike, cheering and supporting the Doylestown Bike Works p/b Fred Beans Cycling Team, and visiting the planet’s best bike shop.

For more information about us, visit Qrumpharma on-line at or email us at [email protected]

Share It
Facebook Twitter Link Share